Treatable Traits in Airway Disease: From Theory to Practice

Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision medicine of airway diseases, a strategy based on the identification and treatment of so-called “treatable traits” (TTs) has been proposed. A TT is a recognizable phenotypic or endotypic characteristic that can be assessed and successfully targeted by therapy to improve a clinical outcome in a patient with airway disease. Importantly, TTs can coexist in the same patient, so they are not mutually exclusive. The TT strategy proposes to investigate in each individual patient with chronic airway disease the number and type of TTs present and to treat each of them according to guideline recommendations. This strategy is agnostic (ie, independent) to the traditional diagnostic labels (asthma, chronic obstructive pulmonary disease), so it can be applied to any patient with airway disease. Currently, there is firm evidence supporting the adequacy and validity of the TT strategy. Here, we review the current state of the art of this topic, first by presenting its theoretical background and then by discussing how to best implement it in clinical practice.
Puedes leer el artículo completo aquí: https://www.sciencedirect.com/science/article/abs/pii/S2213219823000764?dgcid=author
Autores: Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald
Noticias relacionadas

2023 GOLD Report proposes a new definition of chronic obstructive pulmonary disease
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»

La Facultad de Medicina de Barcelona recibe este año la X edición de LUNG CONFERENCE BOSTON
El pasado mes de febrero la UB celebró en su sala Paraninfo La “Barcelona Boston Lung Conference”, un foro anual de debate científico al más alto nivel sobre diversos aspectos de las enfermedades respiratorias, con un elenco de ponentes del máximo nivel internacional.

Comité Científico ChestAir, celebrado en Madrid los días 3 y 4 de Marzo de 2023 con la participación de Alvar Agustí
Àlvar Agustí ha participado en este evento como miembro del comité científico de la reunión, resaltando la importancia de “pasar de una medicina reactiva a una medicina predictiva…»
Más artículos
Estudios
- Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
- Mona Bafadhel, Rosa Faner, Camille Taillé, Richard E.K. Russell, Tobias Welte, Peter J. Barnes and Alvar Agustí. Inhaled corticosteroids for the treatment of COVID-19
- Vincent Cottin et Al. Syndrome of Combined Pulmonary Fibrosis and Emphysema. An Official ATS/ERS/JRS/ALAT Research Statement.
- Bartolome R Celli, Dave Singh, Claus Vogelmeier & Alvar Agusti. New Perspectives on Chronic Obstructive Pulmonary Disease.
- Teresa M Kole et Al. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en Canva Pro el 02/02/2023 libre de derechos para difusión en blog.